SCHEMBL17100613

SCHEMBL17100613

Fc1ccc(Cc2noc(N3CCN(CCc4ccc(Cl)cc4)CC3)n2)cc1F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCC1 P33527 8/20 0.42
HTR1A P08908 3/20 0.41
DRD2 P14416 3/20 0.41
HTR2A P28223 3/20 0.41
DRD3 P35462 3/20 0.41
TMEM97 Q5BJF2 3/20 0.41
SIGMAR1 Q99720 3/20 0.41
DRD1 P21728 1/20 0.41
DRD5 P21918 1/20 0.41
CYP3A4 P08684 5/20 0.41
OPRL1 P41146 2/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HTR2C P28335 2/20 0.39
HRH1 P35367 1/20 0.39
ADRA1D P25100 1/20 0.38
ADRA1A P35348 1/20 0.38
ADRA1B P35368 1/20 0.38
DRD4 P21917 1/20 0.38
HTR7 P34969 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17100651 0.91 SMN1; SMN2 (0.46) DRD2DRD3SIGMAR1RAB9ASMN1; SMN2
SCHEMBL17100670 0.90 L3MBTL1 (0.43) HTR1ADRD2HTR2ADRD3TMEM97
SCHEMBL17100749 0.90 L3MBTL1 (0.43) HTR1ADRD2HTR2ADRD3TMEM97
SCHEMBL17100964 0.83 OPRL1 (0.43) HTR1ADRD2HTR2ADRD3CYP3A4
SCHEMBL18639406 0.83 DRD2 (0.52) HTR1ADRD2HTR2ADRD3TMEM97
SCHEMBL17100759 0.83 MAPT (0.51) ABCC1HTR1ADRD2HTR2ADRD3
SCHEMBL17100717 0.82 SIGMAR1 (0.54) ABCC1HTR1ADRD2SIGMAR1CYP3A4
SCHEMBL17100841 0.82 ABCC1 (0.42) ABCC1CYP3A4RAB9ASMN1; SMN2
SCHEMBL18624607 0.81 ABCC1 (0.46) ABCC1CYP3A4RAB9ASMN1; SMN2
SCHEMBL17100722 0.81 SIGMAR1 (0.41) ABCC1HTR1ADRD2HTR2ADRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US claimed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US claimed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 EP claimed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO claimed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 EP disclosed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562869-B2 Oxadiazole compounds OXA1L, PSEN1, MAPT ABCC1 502/4885HTR1A 1856/4885DRD2 1401/4885
US-20200140400-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT ABCC1 538/4885HTR1A 1955/4885DRD2 1449/4885
US-20170073319-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT ABCC1 502/4885HTR1A 1856/4885DRD2 1401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.